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Accepted 26 February 2013The discovery of the BCR-ABL fusion gene was a landmark
in our understanding of the molecular basis of chronic
myeloid leukemia (CML) [1]. This led rapidly to the demon-
stration that BCR-ABL transcripts could be identiﬁed using
the PCR [2]. Next, it was shown that some patients in
complete cytogenetic remission after an allogeneic trans-
plantation had no detectable BCR-ABL transcripts in their
blood or bone marrow [3]. A technically rather demanding
technique for quantitating BCR-ABL transcripts was then
developed [4], which showed that, at least for CML patients,
blood and marrow gave comparable results. The advent of
Taqman methodology greatly simpliﬁed measurement of
BCR-ABL transcripts in the blood of transplant recipients and
today results are routinely expressed as a ratio of BCR-ABL
transcript numbers related to a control gene. This ratio is
usually reported as a percentage on a log scale, where 100%
reﬂects a hypothetical untreated patient with CML. A patient
with a 3-log reduction (0.1%) in BCR-ABL transcript numbers
is said to have achieved a major molecular response and
a patient with no detectable transcripts is said to be in
complete molecular response (CMR).
Another landmark was the report by Kolb and colleagues
in 1990 that patients in relapse after an allotransplantation
could be treated successfully by infusion of lymphocytes
collected from the original donor togetherwith interferon [5].
Later, it was shown that this effect resulted from the donor
lymphocytes and not interferon [6]. The capacity for these
donor lymphocyte infusions (DLI) to restore CMR is presumed
to be due to a “graft-versus-leukemia” effect and this obser-
vation remains one of the most convincing examples of the
potential beneﬁcial effect of immune therapy in man.
Kaeda et al. reported in 2006 that patients in seeming
complete remission posttransplantation sometimes had
BCR-ABL transcripts detected at low levels, yet relapse was
not inevitable and subsequent testing may show no evidence
of transcripts without any further therapy [7]. Because of the
potential to treat the patients in relapse with DLI, it became
important to agree on a deﬁnition of relapse and it was
proposed that a patient with a transcript level of >.02% on 3Financial disclosure: See Acknowledgments on page 680.
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classiﬁed as having relapsed and would therefore be
a candidate to receive DLI. This, of course, raised the question
of whether these low spikes of BCR-ABL positivity that then
disappeared might actually predict much later relapse.
In the accompanying paper, Arpinati and colleagues report
the results of following a series of allotransplant recipients over
a 24-year period in Bologna [8]. Eleven of the 63 evaluable
patients never had BCR-ABL transcripts detected; none
relapsed. Six of the 52 patients who had BCR-ABL transcripts
detected at least once posttransplantation relapsed. Relapse
was deﬁned as achieving transcripts levels in excess of 0.1%
conﬁrmed by the ﬁnding of Ph-chromosome positive meta-
phases in the bone marrow. Though the deﬁnition of relapse
employed by Kaeda et al. was stricter than that employed by
Arpinati et al., the results of the 2 studies are consistent; both
studies showed that patients with persistent absence of
detectable transcripts never relapsed. Patients who intermit-
tently had low levels of transcripts detected did not inevitably
relapse. Some but not all of the patients with higher levels of
BCR-ABL transcripts posttransplantationwere at riskof relapse.
The conclusion must be that intermittent low-level positivity
should not be interpreted as presaging hematologic relapse.
Taken together, these 2 papers raise a series of chal-
lenging questions. First, from where do these BCR-ABL
transcripts detected posttransplantation actually come? Do
they originate from residual leukemia cells that are clinically
undetectable, from leukemia stem cells that were not erad-
icated by the transplantation, or from both? Why then do
leukemia cells or stem cells respond to DLI later, as most
usually do? Even at this stage, do some leukemia stem cells
escape eradication because they are transcriptionally silent
and so produce no BCR-ABL protein?
Second, do leukemia stem cells survive in all patients after
an allotransplant? Late relapse can occur. A recent study from
the International Center for Blood and Marrow Transplant
Research [9] reported relapses occurring up to 18 years
posttransplantation. Where were the stem cells that gener-
ated relapse lodged for so long?Were they held in a quiescent
state by cytokine inﬂuences in a stem cell niche? If so, why
and how did they escape control? Could this re-emergence
result from a weakened graft-versus-leukemia effect and if
so, why? Is there an analogous situationwith tyrosine kinase
inhibitors (TKIs)? Most patients who achieve CMR with TKIs
relapse when the drug is stopped again, suggesting that TKIs
are highly effective in controlling most leukemia cells but
perhaps not in eradicating leukemia stem cells.
Finally, can we use modern technology to identify
residual leukemia stem cells after an allotransplantation and
should we be concerned by positive ﬁndings? Some recent
data suggest a PCR based on genomic DNA rather than RNA
expression may be a more sensitive technique to detect
S.Z. Usmani / Biol Blood Marrow Transplant 19 (2013) 679e681680residual leukemia [10]. This makes sense if the BCR-ABL
transcripts currently detected come only from proliferating
leukemia cells and while leukemia stem cells may not tran-
scribe the BCR-ABL gene. Will digital PCR increase the
sensitivity of a RT-PCR? Should we be studying CML patients
posttransplantation with techniques designed to mobilize
leukemia stem cells from their niche?
Much has been achieved in the treatment of CML trans-
plantations and TKIs in recent years. Many fascinating
questions remain to be addressed.
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early 1960s [1-3], melphalan has remained a key component
of the oncologist’s armamentarium. High-dose melphalan
therapy was introduced in the early 1980s [4] and has since
been employed with stem cell rescue for “younger”
myeloma patients, with the age limit now pushing 75 years
with advances in supportive care measures [5]. The era of
novel drug development has reawakened the debate of
whether or not to approach the disease with a curative
intent [6]. Some investigators have gone as far as proposing
a pre-emptive strike with novel agent combinations in
smoldering myeloma [7], but a similar approach with
thalidomide has not provided improvements in overall
survival [8]. The Arkansas Myeloma investigators have been
proponents of a curative approach long before the era of
novel agents, proposing the Total Therapy (TT) program that
applies all effective antimyeloma therapies up front to
eradicate all disease subclones and reduce the chance for
drug resistance [9]. Melphalan has been at the front andcenter of the TT program, employed in high doses twice with
stem cell rescue. To this day, myeloma therapy for
transplant-eligible patients follows the TT paradigm in many
ways; the only major difference has been the replacement of
cytotoxic drugs with novel agents as induction, consolida-
tion, and maintenance. Regardless of the therapeutic
approach, most myeloma patients today relapse sooner or
later after having received ﬁrst-line therapy. High-dose
melphalan with stem cell rescue remains a viable option
for salvage therapy, even with the growing number of novel
drugs for relapsed and/or refractory myeloma.
In the current issue, Michaelis et al. [10] report on the role
of employing high-dose melphalan with stem cell rescue as
salvage therapy for relapsed and/or refractory myeloma.
Using the Center for International Blood and Marrow
Transplantation database, a retrospective study was con-
ducted on 187 patients between 1995 and 2008 who had
previously received an autologous hematopoietic stem cell
transplant (AHCT-1) as part of initial myeloma therapy and
subsequently received a second AHCT (AHCT-2) at the time
of disease relapse or progression. The nonrelapse mortality
was reported at 2% at the 1-year mark and 4% at the 2-year
and 3-year intervals, suggesting that AHCT-2 is a safe
option. It is also clear that AHCT-2 is likely noncurative for
the majority of patients in this analysis, as only 5% of patients
enjoy long-term disease control with longer follow-ups
(progression-free survival 47% at 1 year; 13% at 3 years; 5%
at 5 years). The multivariate analyses reveal that patients
who relapse after 36 months from AHCT-1 are those who
beneﬁt the most from AHCT-2. A further subgroup analysis
by time stratiﬁcation shows that patients receiving AHCT-2
after the year 2004 have superior outcome compared to
